Coloplast As Sp/Adr (CLPBY) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, welcome to the Coloplast Interim Financial Statement for H1 2025-26 Conference Call. I'm Lorenzo, the Chorus Call Operator. I would like to remind you that all participants will be in listen-only mode and the conference is being recorded. The presentation will be followed by a Q&A session. You can register for questions at any time by pressing star and 1 on your telephone. For operator assistance, please press star and 0 The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Andras Loning-Skovkart, Executive Vice President and CFO. Please go ahead, sir. Thank you. I'm Anders Lange Skogård, CFO of Coloplast, and I'm very happy to introduce our new president and CEO, Gavin Wood, who joined the company on May 1st. Please turn to slide number three. Thank you, Anders, and good morning, everyone. As Anders mentioned, I joined Coloplast on May 1st, and this is my first opportunity to speak with many of you. So let me briefly introduce myself and share what excites me about joining Coloplast for this next chapter. I've spent more than two decades in global medtech, leading commercial organizations and multibillion-dollar businesses across different regions and therapeutic areas. Most recently, I served as company group chair of Johnson & Johnson MedTech, Ameya, with an organization of more than 7,000 employees and ownership across surgery, orthopedics, and cardiovascular solutions. Prior to this, I was the worldwide president of Ethicon's wound closure and healing business, and before that, the executive vice president of global commercial at Monlica. I started my MedTech career as a sales rep, at Ethicon Endosurgery, followed by a series of traditional roles across sales and sales management. I...